key: cord-0771058-pez25qrw authors: Wang, Li‐Tzu; Liu, Ko‐Jiunn; Sytwu, Huey‐Kang; Yen, Men‐Luh; Yen, B. Linju title: Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell‐free products and human pluripotent stem cell‐derived mesenchymal stem cells date: 2021-05-19 journal: Stem Cells Transl Med DOI: 10.1002/sctm.21-0021 sha: 8bf81d2446dd39b683e5cdae56d05a2cc4c112ee doc_id: 771058 cord_uid: pez25qrw Mesenchymal stem cell therapy (MSCT) for immune and inflammatory diseases continues to be popular based on progressive accumulation of preclinical mechanistic evidence. This has led to further expansion in clinical indications from graft rejection, autoimmune diseases, and osteoarthritis, to inflammatory liver and pulmonary diseases including COVID‐19. A clear trend is the shift from using autologous to allogeneic MSCs, which can be immediately available as off‐the‐shelf products. In addition, new products such as cell‐free exosomes and human pluripotent stem cell (hPSC)‐derived MSCs are exciting developments to further prevalent use. Increasing numbers of trials have now published results in which safety of MSCT has been largely demonstrated. While reports of therapeutic endpoints are still emerging, efficacy can be seen for specific indications—including graft‐vs‐host‐disease, strongly Th17‐mediated autoimmune diseases, and osteoarthritis—which are more robustly supported by mechanistic preclinical evidence. In this review, we update and discuss outcomes in current MSCT clinical trials for immune and inflammatory disease, as well as new innovation and emerging trends in the field. Mesenchymal stem/stromal cells (MSCs) are multipotent progenitor cells capable of supporting hematopoiesis and differentiation into the multiple mesodermal lineages of osteoblasts, chondrocytes, and adipocytes. [1] [2] [3] First found in the bone marrow (BM), MSCs have been isolated from numerous organs/tissues over the past several decades, but in vivo identity remains somewhat elusive, with increasing evidence for a perivascular origin. [4] [5] [6] An unexpected function of MSCs-especially prominent with human sources-is its strong immunomodulatory properties, which have been best delineated toward CD4 cells but also well characterized against a variety of myeloid and innate leukocytes, including dendritic cells, monocytes, and macrophages. [7] [8] [9] While initial preclinical data of MSC therapeutic efficacy were mainly focused on regenerative and differentiation capacity, it quickly became apparent that the immunomodulatory properties not only are clinically relevant but allow for allogeneic, unmatched use of these progenitor cells. The application of MSCs toward immune and inflammatory diseases rapidly ensued, with a doubling of clinical trials for these conditions within the past 5 years. 10 Moreover, discoveries of new mechanisms and new products-including using MSC-derived products and human pluripotent stem cell (hPSC) including embryonic stem cell (ESC) and induced PSC (iPSC)-derived MSCs-as well as emerging diseases such as COVID-19 has continued to widen the clinical application of MSC immunomodulation. 11 We therefore review the current status of clinical trials using MSC therapy (MSCT) for inflammatory or immune-related diseases and discuss new advances in the field. The immunomodulatory properties of MSCs are well demonstrated toward both lymphoid and myeloid cells, with increasing accumulation of mechanistic evidence (Figure 1 ). MSC immune functions have been best documented against CD4 T lymphocytes, a critical leukocyte population in orchestrating overall immune responses. Numerous reports have shown that MSCs modulate these adaptive cells from an inflammatory milieu filled predominantly with effector T cells to a regulatory T (Treg)-rich microenvironment largely through paracrine factors, most commonly through transforming growth factor beta (TGF-β), hepatocyte growth factor (HGF) 12 prostaglandin E 2 (PGE 2 ), 13 nitric oxide (NO), and indoleamine 2,3-dioxygenase (IDO). 8, [14] [15] [16] While a few studies found cell-cell contact involved in MSC-T cell immunomodulation, 17 this mechanism is more prominent in MSC-NK interactions, involving downregulation of activating NK receptors F I G U R E 1 Mechanisms of mesenchymal stem cell (MSC) immunomodulation toward lymphoid and myeloid cells as evidenced in preclinical in vivo studies. NK, natural killer cell; PMN, polymorphonuclear neutrophil; MΦ, macrophage; MDSC, myeloid-derived suppressor cell; DC, dendritic cell; PGE 2 , prostaglandin E2; IDO, Indoleamine 2,3-dioxygenase; HLA-G, human leukocyte antigen-G; TGF-β, transforming growth factor beta; Gal, galectin; IL, Interleukin; NO, nitric oxide; HO-1, heme oxygenase-1; HGF, hepatocyte growth factor; PD-L, programmed death-ligand; IL-1RA, interleukin-1 receptor antagonist; CCL2, chemokine ligand 2; TSG-6, TNF-stimulated gene 6 protein; SOD3, superoxide dismutase 3; SCT-1, stanniocalcin-1; IGF-1, insulin-like growth factor-1; KGF, keratinocyte growth factor; GRO-γ, growth related oncogene γ. Cell-contact factors are denoted in brackets such as KIR, NKp30, NKp44 and NKG2D through MSC-expressed surface and soluble HLA-G, a non-classical MHC class I molecule important in fetal-maternal immunomodulation. 18,19 Interestingly, immunomodulatory paracrine factors such as PGE 2 and IDO inducible by inflammatory signals including IFN-γ and IL-1β are prominent in MSC interactions across leukocyte subpopulations including all lymphoid cells including T cells, NKs, 20 and B cells in which IL-10-expressing regulatory B cells are expanded. 21, 22 Reports are most scarce for MSC-B cell interactions, but most demonstrate suppression of B cell proliferation, differentiation, and antibody production [23] [24] [25] [26] [27] [28] [29] ; our recent report found that MSC-B cell interactions may be more complex than previously thought due to MSC source-specific differences in expression of relevant factors. 30 Such information on tissue-specific MSC properties may provide insights which could prove relevant for clinical application. 11, 31 The broad reach of MSC immunomodulation is best exemplified by interactions with myeloid cells, which are much more heterogenous than lymphoid cells. Among early reports of MSC modulation are studies on dendritic cells (DCs)-professional antigen-presenting cells that initiate T cell response-in which MSC paracrine factors including IL-6, 32 PGE 2 , 33 and growth-regulated oncogene (GRO)-γ, 34 as well as cell-cell contact through Jagged-2 35 , suppress maturation and lead to the development of regulatory DCs, which are more immature and tolerogenic. MSCs have also been seen to inhibit activation of macrophages and/or induce polarization into an alternative M2 phenotype which are critical in resolving inflammation, with data indicating involvement of paracrine factors including IL-1RA, 36 45 and multiple anti-bacterial functions of PMNs through IL-1β secretion. 48 Such accumulation and broadening of evidence for MSC interactions with numerous leukocyte populations is extremely relevant for better tailoring of MSCT-that is, determine which tissuespecific sources or cell-derived products to use-for more effective targeting of specific diseases and/or patient subpopulations. Table 1) . Only a few trials are in Phase 3 to determine effectiveness (n = 18 or 3.7%), combined Phase 2/3 studies remarkably, there is a very recent trial using iPSC-MSCs (n = 1). However, 28 trials did not specify the source of MSCs, and two used MSC-derived products with one using exosomes from WJUCMSCs and one using conditioned medium (CM) from unspecified MSCs. Notes: a Trial using two sources of MSCs: WJUC and amnion; b,c,d,e,f Trials using two sources of MSCs: BM and WJUC; g Trial using two sources of MSCs: BM and placenta; i Trial using two sources of MSCs: BM and adipose; h Trial using two sources of MSCs: BM and cord blood; j,k,l Trials using both the MSC and its derived products. A Reprogrammed from peripheral blood mononuclear cells. B Exosomes or trophic factors collected from conditioned medium. Interestingly, the majority of trials use allogeneic rather than autologous MSCs (57 vs 16 trials, respectively), while one trial used both types and 19 trials were undefined. Because graft rejection was the first clinical application of MSCT, this field has the most published studies of clinical data so far, with nine reports on GVHD and 11 reports on solid organ transplantation. Several adult and pediatric trials-including two Phase 3 trials-for steroid-refractory acute or chronic GVHD using intravenous infusion of allogenic BMMSCs at doses of 1$2 Â 10 6 /kg showed significant therapeutic efficacy and safety [63] [64] [65] [66] [67] [68] ; moreover, co-transplantation of BMMSCs at the time of HSCT was found to prevent GVHD progression and/or occurrence. 69, 70 One of the most exciting results is a Phase 1 trial published this year using allogeneic iPSC-MSCs for steroid-resistant acute GVHD, in which safety and some efficacy was seen. 71 Interestingly, for solid organ rejection, all seven published reports used autologous BMMSCs for renal transplantation, 72-77 and pancreatic islet cell transplantation. 78 Immunosuppressive drugs were used in all these studies except in the islet cell transplantation study and all demonstrated safety, with some efficacy seen in these studies. Allogeneic BMMSCs or WJUCMSC were used in two studies of renal transplantation, and no toxicity was seen. 79, 80 When considering the efficacy of allogenic MSCs, WJUCMSCs was reported to successfully prevent both delayed graft function and acute rejection in renal transplantation, 81 whereas BMMSCs were not found to induce immunosuppression in a report on liver transplantation. 82 These published results overall demonstrate that for graft rejection, MSCT is safe and may be efficacious, especially for pediatrics cases of GVHD where allogeneic BMMSC therapy may be particularly beneficial. Autoimmune diseases are disorders in which the body's immune system attacks its own cells and organs, and autoreactive T WJUCMSCs to CD and ulcerative colitis (UC) patients also reduced mucosal inflammation. 87, 88 The six published reports using autologous BMMSCs administered intravenously or intrathecally for MS demonstrated safety and some non-significant reduction of inflammatory parameters [89] [90] [91] [92] [93] [94] ; two other reports utilized allogeneic WJUCMSCs, with one study still ongoing 95 The high entrapment of cells within the lungs after intravenous injection-the most common method to deliver cell therapy-has long been known, and can be taken advantage of in MSCT for pulmonary diseases. 134 As an organ open to the environment, a number of infec- allogeneic BMMSCs. 148 Clinical results of MSCT for lung diseasesespecially COVID-19-are highly anticipated because of the invaluable information these numerous trials will provide on the efficacy of not only MSCT but also MSC-related products. Liver fibrosis or cirrhosis is the end-stage manifestation of many hepatic diseases, ranging from infectious insults due to hepatitis viruses B and C, to non-infectious conditions such as alcohol abuse and non-alcoholic fatty liver disease; it is also a risk factor for hepatocellular carcinoma formation. 149 Compared with other organ systems, 156 We also recently demonstrated that PMSC treatment in a mouse model of hypervirulent Klebsiella-induced severe intra-abdominal infection can enhance neutrophil bactericidality to reduce liver injury and increase survival. 48 In a mouse model of autoimmune cholangitis, liver inflammation was reduced through WJUCMSC-secreted Gal-9. 157 These increasing numbers of preclinical reports support that MSC immunomodulation may be efficacious toward hepatitis and cirrhosis. Currently, there are 40 registered trials of MSCT for liver failure involving viral hepatitis or cirrhosis, with trials predominantly in early phase: six trials in Phase 1, 12 in Phase 2, and 18 in combined Phase1/2 (Table S5) showed limited improvement on short-term outcome of HBV-related liver failure patients. 159 Further accumulation of clinical data is urgently needed to assess whether MSCT is efficacious for inflammation-mediated liver failure and/or cirrhosis. While the minimal reports of adverse events so far in the large number of MSC clinical trials are reassuring, efficacy has been as easy to achieve as was expected. This has increasingly led to the idea that MSC immunomodulation may be represent short-term immune evasion rather than long-term immune privilege, and that the MSC itself likely rapidly undergo apoptosis after administration. 160 165 macrophages, 166 and DCs. 167 To date, there are 16 trials using MSC-derived products including CM, EVs, or exosomes: three trials are in Phase 1, two in Phase 2, seven are combined Phase 1/2, two are combined Phase 2/3 trials, and two did not specify phase (Table 2) . Interestingly, most of the trials (n = 10) are for pulmonary diseases, 11 (Table S6 ). It can be anticipated that clinical trials using MSC-derived products-readily available as off-the-shelf products-will continue to increase. The ability to isolate MSCs from a myriad of organs/tissues does not solve the problem that all tissue-derived MSCs undergo senescence, which not only decreases proliferative capacity but differentiation capacity as well. 168 These concerns can be precluded with stringent QA/QC protocols to exclude undifferentiated and genetically unstable cells. 177 In addition, the functional variability with primary-isolated human samples and cell products is avoided since MSCs can be generated from a particular ESC or iPSC line essentially indefinitely to continually provide functionally stable lots of cells and cell products. 178 milestone. 71 Based on increasing preclinical data and these four sentinel trials, it is anticipated that more clinical trials using hPSC-derived MSCs will be conducted. Although there are over 1000 trials using various types of MSCs or MSC-free derivatives being conducted in more than 40 countries, only nine MSC-based products have been approved worldwide for either regenerative or immune-related diseases. 187 Encouragingly, these approved MSC-based products overwhelmingly except for one prod- While clinical effectiveness is ultimately the criteria for approval of therapeutic products, the low numbers of approved MSC products also reflect large national/regional differences in regulation for cellbased products, 188 as well as difficulties in transitioning from preclinical to clinical platforms. 189 MSC products in particular suffers from a lack of agreement on robust and relevant characterization criteria for clinical reliability and functionality; the current Minimal Criteria for MSCs date back nearly two decades and was not established for clinical use nor take into account immunomodulatory properties which were largely discovered after these criteria were agreed upon. Moreover, "gold standard" double-blind randomized clinical trialincluding testing for critical parameters such as dose, delivery route, and timing-are clearly more difficult to conduct with complex and live cell-based products than pharmaceutical products. 178 Continually progress to overcome these hurdles is occurring which should allow for clinical effectiveness to be more evident in the near future. 187 GVHD, predominately Th17-mediated autoimmune diseases such as IBD and MS, and OA in which both the regenerative and immunomodulatory capacity of MSCs can be useful. New developments in use of cell-free products and iPSC-MSCs, as well as more preclinical data on tissue-specific differences in MSC sources are all likely to further improve MSCT outcomes in the very near future. The authors declared no potential conflicts of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study. B. Linju Yen https://orcid.org/0000-0002-6905-3018 Precursor cells of mechanocytes Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment A perivascular origin for mesenchymal stem cells in multiple human organs The elusive nature and function of mesenchymal stem cells Mesenchymal stem cells in health and disease Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells Multipotent mesenchymal stromal cells and the innate immune system Human mesenchymal stem cells (MSCs) for treatment towards immune-and inflammationmediated diseases: review of current clinical trials Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: gleaning insights for possible use in COVID-19 Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli Human mesenchymal stem cells modulate allogeneic immune cell responses Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells New insights into mesenchymal stromal cell-mediated Tcell suppression through galectins Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 +CD25highFOXP3+ regulatory T cells Surface expression of HLA-G is involved in mediating immunomodulatory effects of placentaderived multipotent cells (PDMCs) towards natural killer lymphocytes Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2 Mesenchymal stromal cells attenuate multiple sclerosis via IDO-dependent increasing the suppressive proportion of CD5+ IL-10+ B cells Human mesenchymal stem cell-treated regulatory CD23(+)CD43(+) B cells alleviate intestinal inflammation Impaired B cell inhibition by lupus bone marrow mesenchymal stem cells is caused by reduced CCL2 expression Mesenchymal stem cellderived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation Human mesenchymal stem cells modulate B-cell functions Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway Mesenchymal stem cells ameliorate B-cell-mediated immune responses and increase IL-10-expressing regulatory B cells in an EBI3-dependent manner Resident vs nonresident multipotent mesenchymal stromal cell interactions with B lymphocytes result in disparate outcomes Efficacy of mesenchymal stromal cell therapy for acute lung injury in preclinical animal models: a systematic review Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSCderived prostaglandin E2 Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation Molecular crosstalk between macrophages and mesenchymal stromal cells Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-met and STAT3 Mesenchymal stem/stromal cells protect against autoimmunity via CCL2-dependent recruitment of myeloid-derived suppressor cells Mesenchymal stromal cells induce distinct myeloid-derived suppressor cells in inflammation Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche The effect of conditioned medium derived from human placental multipotent mesenchymal stromal cells on neutrophils: possible implications for placental infection TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo Suppression of neutrophilmediated tissue damage-a novel skill of mesenchymal stem cells Human placental MSCsecreted IL-1beta enhances neutrophil bactericidal functions during hypervirulent Klebsiella infection Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group OTI-010 osiris therapeutics/JCR pharmaceuticals Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferongamma IL-1beta enhances human placentaderived mesenchymal stromal cells ability to mediate Th1/Th2 and Th1/CD4(+)IL-10(+) T cell balance and regulates its adhesion, proliferation and migration via PD-L1 Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells Stro-1-positive human mesenchymal stem cells prolong skin graft survival in mice Interleukin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts Prevention of acute liver allograft rejection by IL-10-engineered mesenchymal stem cells Protective effects of mesenchymal stem cells with CXCR4 up-regulation in a rat renal transplantation model Immunomodulatory effects of mesenchymal stem cells in a rat corneal allograft rejection model iPSC-derived MSC therapy induces immune tolerance and supports long-term graft survival in mouse orthotopic tracheal transplants Mesenchymal stromal cells in solid organ transplantation Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: a phase II study A phase 3 randomized study of Remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease A phase 3, single-arm, prospective study of Remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graftversus-host disease Study 275: updated expanded access program for Remestemcel-L in steroid-refractory acute graft-versus-host disease in children Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, doseescalation study Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients Long-term clinical and immunological profile of kidney transplant patients given mesenchymal stromal cell immunotherapy Autologous mesenchymal stem cell and islet cotransplantation: safety and efficacy Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial Allogeneic mesenchymal stem cell as induction therapy to prevent both delayed graft function and acute rejection in deceased donor renal transplantation: study protocol for a randomized controlled trial Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase I-II, open-label, clinical study Allogeneic bone marrowderived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn's disease Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, doubleblind controlled trial Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn's disease Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn's disease A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study Randomized placebocontrolled phase II trial of autologous mesenchymal stem cells in multiple sclerosis Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis MEsenchymal StEm cells for multiple sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis The effect of stem cell therapy and comprehensive physical therapy in motor and nonmotor symptoms in patients with multiple sclerosis: a comparative study Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebocontrolled phase Ib/IIa clinical trial Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: results of a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial Intravenous infusion of allogeneic mesenchymal stromal cells in refractory or relapsed aplastic anemia Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS trial protocol Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion Allogenic adipose tissuederived stromal/stem cells and vitamin D supplementation in patients with recent-onset type 1 diabetes mellitus: a 3-month follow-up pilot study Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study A randomised double-blind, placebocontrolled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study Th17 plasticity and its relevance to inflammatory bowel disease The role of TH17 cells in multiple sclerosis: therapeutic implications Role of inflammation and the immune system in the progression of osteoarthritis Mesenchymal stem cells in joint disease and repair TGFbetai is involved in the chondrogenic differentiation of mesenchymal stem cells and is dysregulated in osteoarthritis Adipose-derived mesenchymal stem cells exert antiinflammatory effects on chondrocytes and synoviocytes from osteoarthritis patients through prostaglandin E2 Adipose stromal cells mediated switching of the pro-inflammatory profile of M1-like macrophages is facilitated by PGE2: in vitro evaluation IL-1beta-mediated activation of adipose-derived mesenchymal stromal cells results in PMN reallocation and enhanced phagocytosis: a possible mechanism for the reduction of osteoarthritis pathology Effect of arthritic synovial fluids on the expression of immunomodulatory factors by mesenchymal stem cells: an explorative in vitro study Long-term followup of intra-articular injection of autologous mesenchymal stem cells in patients with knee, ankle, or hip osteoarthritis Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II) Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II) Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a 2-year follow-up study Human adipose-derived mesenchymal stem cells for osteoarthritis: a pilot study with long-term follow-up and repeated injections Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, activecontrolled, phase IIb clinical trial Human adipose-derived mesenchymal progenitor cells plus microfracture and hyaluronic acid for cartilage repair: a phase IIa trial Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel(R)): preclinical and clinical trial in osteoarthritis of the knee joint Influence of HLA matching on the efficacy of allogeneic mesenchymal stromal cell therapies for osteoarthritis and degenerative disc disease Multi-compositional MRI evaluation of repair cartilage in knee osteoarthritis with treatment of allogeneic human adipose-derived mesenchymal progenitor cells Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial Tracking of infused mesenchymal stem cells in injured pulmonary tissue in Atm-deficient mice Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): a structured summary of a study protocol for a randomised controlled trial Design and implementation of the START (STem cells for ARDS treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment ofmoderate-severe acute respiratory distress syndrome A placebo-controlled, randomized trial of mesenchymal stem cells in COPD A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema Adipose-derived mesenchymal stem cells ameliorate lung epithelial injury through mitigating of oxidative stress in mustard lung Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I safety clinical trial The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: a multicenter prospective cohort study Repair of acute respiratory distress syndrome by stromal cell administration in COVID-19 (REALIST-COVID-19): a structured summary of a study protocol for a randomised, controlled trial Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (phase I / II) Transplantation of ACE2(À) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia Hepatocellular carcinoma in cirrhosis: incidence and risk factors Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice Mesenchymal stem cells attenuate liver fibrosis by suppressing Th17 cells-an experimental study Multipotent mesenchymal stromal cells synergize with costimulation blockade in the inhibition of immune responses and the induction of Foxp3+ regulatory T cells Mesenchymal stromal cell-dependent reprogramming of Kupffer cells is mediated by TNF-alpha and PGE2 and is crucial for liver transplant tolerance Bone marrow-derived mesenchymal stem cells suppress NK cell recruitment and activation in PolyI:C-induced liver injury Tumor necrosis factor-inducible gene 6 promotes liver regeneration in mice with acute liver injury Extracellular vesicles derived from human embryonic stem cell-MSCs ameliorate cirrhosis in thioacetamide-induced chronic liver injury Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9 Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study Combination treatments of plasma exchange and umbilical cord-derived mesenchymal stem cell transplantation for patients with hepatitis B virus-related acute-onchronic liver failure: a clinical trial in China Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation Mesenchymal stem cells: immune evasive, not immune privileged Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation Therapeutic application of mesenchymal stem cells derived extracellular vesicles for immunomodulation Mesenchymal stromal cell-derived exosomes affect mRNA expression and function of B-lymphocytes Human fetal liver mesenchymal stem cell-derived exosomes impair natural killer cell function Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophagedependent mechanism Effect of mesenchymal stem cell-derived exosomes on the induction of mouse tolerogenic dendritic cells Replicative senescence of mesenchymal stem cells: a continuous and organized process H2O2 accumulation mediates differentiation capacity alteration, but not proliferative decline, in senescent human fetal mesenchymal stem cells Scalable generation of mesenchymal stem cells and adipocytes from human pluripotent stem cells Derivation of multipotent mesenchymal precursors from human embryonic stem cells Efficient derivation and concise gene expression profiling of human embryonic stem cell-derived mesenchymal progenitors (EMPs) Characterization and evaluation of mesenchymal stem cells derived from human embryonic stem cells and bone marrow Derivation of clinically compliant MSCs from CD105+, CD24À differentiated human ESCs Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NKcell cytolytic machinery The tumorigenicity of human embryonic and induced pluripotent stem cells Autologous induced stem-cellderived retinal cells for macular degeneration Lessons learned from pioneering neural stem cell studies Human embryonic stem cellderived mesenchymal stroma cells (hES-MSCs) engraft in vivo and support hematopoiesis without suppressing immune function: implications for off-the shelf ES-MSC therapies Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells Brief report-human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes Differentiation of mesenchymal stem cells from human induced pluripotent stem cells results in downregulation of c-Myc and DNA replication pathways with immunomodulation toward CD4 and CD8 cells Killer Ig-like receptormediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation Transplantation: molecular phenotyping of T-cell-mediated rejection Comprehensive molecular profiles of functionally effective MSC-derived extracellular vesicles in immunomodulation An overview of international regulatory frameworks for mesenchymal stromal cell-based medicinal products: from laboratory to patient FDA rejects Mesoblast flagship treatment Quality cell therapy manufacturing by design Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells